489 related articles for article (PubMed ID: 26398286)
1. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
[TBL] [Abstract][Full Text] [Related]
5. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
Faisal A; Mak GWY; Gurden MD; Xavier CPR; Anderhub SJ; Innocenti P; Westwood IM; Naud S; Hayes A; Box G; Valenti MR; De Haven Brandon AK; O'Fee L; Schmitt J; Woodward HL; Burke R; vanMontfort RLM; Blagg J; Raynaud FI; Eccles SA; Hoelder S; Linardopoulos S
Br J Cancer; 2017 Apr; 116(9):1166-1176. PubMed ID: 28334731
[TBL] [Abstract][Full Text] [Related]
7. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
[TBL] [Abstract][Full Text] [Related]
9. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
10. MPS1 kinase as a potential therapeutic target in medulloblastoma.
Alimova I; Ng J; Harris P; Birks D; Donson A; Taylor MD; Foreman NK; Venkataraman S; Vibhakar R
Oncol Rep; 2016 Nov; 36(5):2633-2640. PubMed ID: 27633003
[TBL] [Abstract][Full Text] [Related]
11. Two LXXLL motifs in the N terminus of Mps1 are required for Mps1 nuclear import during G(2)/M transition and sustained spindle checkpoint responses.
Zhang X; Yin Q; Ling Y; Zhang Y; Ma R; Ma Q; Cao C; Zhong H; Liu X; Xu Q
Cell Cycle; 2011 Aug; 10(16):2742-50. PubMed ID: 21778823
[TBL] [Abstract][Full Text] [Related]
12. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
13. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
[TBL] [Abstract][Full Text] [Related]
14. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
[TBL] [Abstract][Full Text] [Related]
15. Modulation of miR-21 signaling by MPS1 in human glioblastoma.
Maachani UB; Tandle A; Shankavaram U; Kramp T; Camphausen K
Oncotarget; 2016 Aug; 7(33):52912-52927. PubMed ID: 25991676
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
17. High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
Anderhub SJ; Mak GW; Gurden MD; Faisal A; Drosopoulos K; Walsh K; Woodward HL; Innocenti P; Westwood IM; Naud S; Hayes A; Theofani E; Filosto S; Saville H; Burke R; van Montfort RLM; Raynaud FI; Blagg J; Hoelder S; Eccles SA; Linardopoulos S
Mol Cancer Ther; 2019 Oct; 18(10):1696-1707. PubMed ID: 31575759
[TBL] [Abstract][Full Text] [Related]
18. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
[TBL] [Abstract][Full Text] [Related]
19. Chemical genetic inhibition of Mps1 in stable human cell lines reveals novel aspects of Mps1 function in mitosis.
Sliedrecht T; Zhang C; Shokat KM; Kops GJ
PLoS One; 2010 Apr; 5(4):e10251. PubMed ID: 20422024
[TBL] [Abstract][Full Text] [Related]
20. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]